Ketamine As an Adjunctive Therapy for Major Depression (2)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-13

Study Completion Date

2024-08-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pragmatic, randomised, controlled, parallel-group, superiority trial of ketamine vs. midazolam as an adjunctive therapy for depression. The main purpose of the trial is to assess the mood-rating score difference between ketamine and midazolam from before the first infusion to 24 hours after the final infusion, supplemented by a 95% confidence interval. There will also be a 24-week follow-up after the final infusion session.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketamine as an Adjunctive Therapy for Major Depression

NCT03256162

Major Depressive Episode Unipolar Depression Bipolar Depression

COMPLETED PHASE1

Ketamine for Depression Relapse Prevention Following ECT

NCT02414932

Depression

COMPLETED EARLY_PHASE1

Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression

NCT05026203

Depression

COMPLETED PHASE4

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945

Major Depressive Disorder

COMPLETED NA

Ketamine Trial for the Treatment of Depression

NCT02401139

Unipolar Depression

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pragmatic, randomised, controlled, parallel-group, superiority trial. Trial participants will be patients admitted to St Patrick's University Hospital for treatment of a major depressive episode. The investigators aim to recruit up to 104 participants who will be eligible for this study and randomly allocate 52 patients to each group. Both participants and assessors will be blind to treatment allocation. Eligible consented participants will be randomly allocated in a 1:1 ratio to a course of up to eight infusions of either ketamine or midazolam twice weekly over up to four weeks. Block randomisation will be independently performed. Physical, psychotomimetic and cognitive outcomes will be monitored before, during and after infusions. During the allocated infusions and follow-up period patients will be monitored for treatment-related adverse events relating to both mental and physical health. Participants will also be followed-up for 24 weeks after the end of the initial randomised treatment and assessment period lasting up to four weeks, in order to identify if and when relapse occurs. During the trial, both groups will continue usual inpatient care as prescribed by their treating team.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Episode Unipolar Depression Bipolar Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine

Participants will receive up to a four-week course of twice-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.

Midazolam

Participants will receive up to a four-week course of twice-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.

Group Type ACTIVE_COMPARATOR

Midazolam

Intervention Type DRUG

A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine

A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.

Intervention Type DRUG

Midazolam

A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ketalar Hypnovel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years old.
* Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥ 20 at screening and start of the first infusion.
* Voluntary admission for treatment of an acute depressive episode
* Meet DSM-5 criteria for a major depressive disorder or bipolar affective disorder (current episode depression). Diagnosis of a major depressive disorder or bipolar affective disorder (DSM-5) will be confirmed by the structured diagnostic Mini International Neuropsychiatric Interview (MINI; updated Version 7 for DSM-5).

Exclusion Criteria

* Current involuntary admission.
* Medical condition rendering unfit for ketamine/midazolam.
* Currently taking any of the contraindicated medications that may alter the pharmacokinetics of ketamine.
* Active suicidal intention.
* Dementia.
* Lifetime history of schizophrenia or schizoaffective disorder; active anorexia nervosa or bulimia nervosa in the past 12 months; alcohol or other substance use disorder (with the exception of nicotine) in the previous six months; any DSM-5 disorder other than a major depressive episode (unipolar or bipolar) as the primary presenting problem.
* Electroconvulsive Therapy (ECT) administered within the last two months.
* Pregnancy, breastfeeding or considering becoming pregnancy whilst on the trial for up to 12 weeks after last dose or inability to confirm use of adequate contraception during the trial.
* Breastfeeding women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No